Oncotarget

Research Papers:

ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression

Takashi Kawahara, Hasanain Khaleel Shareef, Ali Kadhim Aljarah, Hiroki Ide, Yi Li, Eiji Kashiwagi, George J. Netto, Yichun Zheng and Hiroshi Miyamoto _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:29860-29876. https://doi.org/10.18632/oncotarget.5007

Metrics: PDF 1083 views  |   HTML 1214 views  |   ?  


Abstract

Takashi Kawahara1,2,3,*, Hasanain Khaleel Shareef1,4,*, Ali Kadhim Aljarah1,5, Hiroki Ide1, Yi Li2,6, Eiji Kashiwagi1, George J. Netto1, Yichun Zheng1,2,6, Hiroshi Miyamoto1,2

1Departments of Pathology and Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

2Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA

3Department of Urology, Yokohama City University School of Medicine, Yokohama, Japan

4Department of Biology, University of Babylon College of Science for Women, Babylon, Iraq

5Department of Biology, University of Baghdad College of Science, Baghdad, Iraq

6Department of Urology, 2nd Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China

*These authors have contributed equally to this work

Correspondence to:

Hiroshi Miyamoto, e-mail: hmiyamo1@jhmi.edu

Keywords: androgen, bladder cancer, ELK1, immunohistochemistry, tumor progression

Received: June 19, 2015     Accepted: August 12, 2015     Published: August 22, 2015

ABSTRACT

Little is known about biological significance of ELK1, a transcriptional factor that activates downstream targets including c-fos proto-oncogene, in bladder cancer. Recent preclinical evidence also suggests the involvement of androgen receptor (AR) signaling in bladder cancer progression. In this study, we aim to investigate the functions of ELK1 in bladder cancer growth and their regulation by AR signals. Immunohistochemistry in bladder tumor specimens showed that the levels of phospho-ELK1 (p-ELK1) expression were significantly elevated in urothelial neoplasms, compared with non-neoplastic urothelium tissues, and were also correlated with AR positivity. Patients with p-ELK1-positive non-muscle-invasive and muscle-invasive tumors had significantly higher risks for tumor recurrence and progression, respectively. In AR-positive bladder cancer cell lines, dihydrotestosterone treatment increased ELK1 expression (mRNA, protein) and its nuclear translocation, ELK1 transcriptional activity, and c-fos expression, which was restored by an anti-androgen hydroxyflutamide. ELK1 silencing via short hairpin RNA (shRNA) resulted in decreases in cell viability/colony formation, and cell migration/invasion as well as an increase in apoptosis. Importantly, ELK1 appears to require activated AR to regulate bladder cancer cell proliferation, but not cell migration. Androgen also failed to significantly induce AR transactivation in ELK1-knockdown cells. In accordance with our in vitro findings, ELK1-shRNA expression considerably retarded tumor formation as well as its growth in xenograft-bearing male mice. Our results suggest that ELK1 plays an important role in bladder tumorigenesis and cancer progression, which is further induced by AR activation. Accordingly, ELK1 inhibition, together with AR inactivation, has the potential of being a therapeutic approach for bladder cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5007